论文部分内容阅读
目的 :比较洛伐他汀与非诺贝特的调脂疗效。方法 :高脂血症 183例随机分为 2组。 92例 (男性5 3例 ,女性 39例 ;年龄 5 4a±s 11a)采用洛伐他汀2 0mg ,po ,bid× 8wk ;另 91例 (男性 5 1例 ,女性40例 ;年龄 5 2a± 12a)采用非诺贝特 10 0mg ,po ,bid× 8wk。结果 :2组均于治疗 4wk开始TC ,TG ,LDL_Ch ,VLDL_Ch下降有非常显著性差异 (P <0 .0 1) ;HDL_Ch有非常显著性升高 (P <0 .0 1) ,2组均于治疗 8wk疗效进一步升高 (P <0 .0 1) ;2组组间比较 ,洛伐他汀组对TC与VLDL_Ch的下降较后者更显著 (P <0 .0 1,P <0 .0 5 ) ;前者体重下降多于后者 (P <0 .0 5 ) ,2组均无严重不良反应。结论 :2组调脂疗效均好 ,而洛伐他汀比非诺贝特更好
OBJECTIVE: To compare the lipid-lowering effects of lovastatin and fenofibrate. Methods: 183 cases of hyperlipidemia were randomly divided into two groups. 92 patients (53 males and 39 females; age 5 4a ± s 11a) were treated with lovastatin 20 mg, po, bid × 8 weeks. Another 91 patients (51 males and 40 females; ) Using fenofibrate 10 0mg, po, bid × 8wk. Results: The levels of TC, TG, LDL_Ch and VLDL_Ch in both groups were significantly decreased at 4wk after treatment (P <0.01), HDL_Ch was significantly increased (P <0.01) (P <0.01). The reduction of TC and VLDL_Ch in lovastatin group was more significant than that in the latter two groups (P <0.01, P <0. 0) 5). The former had more weight loss than the latter (P <0.05), and the two groups had no serious adverse reactions. Conclusion: Both groups had good lipid-lowering effects, while lovastatin was better than fenofibrate